Castle Biosciences Inc . (NASDAQ:CSTL) reported Q2 EPS of ($0.06), $0.70 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $34.84 million versus the consensus estimate of $28.37 million.
Castle Biosciences Inc . (NASDAQ:CSTL) reported Q2 EPS of ($0.06), $0.70 better than the analyst estimate of ($0.76). Revenue for the quarter came in at $34.84 million versus the consensus estimate of $28.37 million.